{
    "id": 20402,
    "fullName": "STAT3 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "STAT3 positive indicates the presence of the STAT3 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6774,
        "geneSymbol": "STAT3",
        "terms": [
            "STAT3",
            "ADMIO",
            "ADMIO1",
            "APRF",
            "HIES"
        ]
    },
    "variant": "positive",
    "createDate": "03/28/2016",
    "updateDate": "08/01/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5397,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OPB-31121 inhibited cell proliferation of Stat3-positive gastric cancer cells in culture and suppressed tumor growth in cell line xenograft models (PMID: 23402820).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3852,
                "therapyName": "OPB-31121",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5045,
                    "pubMedId": 23402820,
                    "title": "OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23402820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5456,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FLLL32 inhibited Stat3 signaling and cell proliferation in osteosarcoma cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 21340507).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3862,
                "therapyName": "FLLL32",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5064,
                    "pubMedId": 21340507,
                    "title": "Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21340507"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8838,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 0617B in combination with Tarceva (erlotinib) significantly enhanced tumor growth inhibition compared to single agent in cell line xenograft models of non-small cell lung cancer (PMID: 27439479).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 4823,
                "therapyName": "Debio 0617B + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6765,
                    "pubMedId": 27439479,
                    "title": "Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27439479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4281,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ISIS-STAT3rx (AZD9150) treatment resulted in stable disease or partial response in 44% (11/25) of patients with advanced solid tumors or lymphoma (PMID: 26582900).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 2782,
                "therapyName": "AZD9150",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4478,
                    "pubMedId": 26582900,
                    "title": "AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582900"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5457,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FLLL32 inhibited Stat3 signaling and induced apoptosis in renal cell carcinoma cell lines in culture (PMID: 22899991).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3862,
                "therapyName": "FLLL32",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5068,
                    "pubMedId": 22899991,
                    "title": "Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22899991"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5453,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FLLL32 inhibited Stat3 signaling and cell proliferation in breast cancer cell lines in culture, and suppressed tumor growth in breast cancer cell line xenograft models (PMID: 20215512).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3862,
                "therapyName": "FLLL32",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5066,
                    "pubMedId": 20215512,
                    "title": "Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20215512"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5510,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WP1066 and Farydak (panobinostat) combination treatment resulted in apoptosis in Stat3-positive chronic lymphocytic leukemia cells resistant to Farydak (panobinostat) (PMID: 25636517).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3874,
                "therapyName": "Panobinostat + WP1066",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5079,
                    "pubMedId": 25636517,
                    "title": "The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25636517"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12384,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PMMB-187 inhibited Stat3 activation and growth of Erbb2 (Her2)-negative breast cancer cell lines in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 29066190).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 6485,
                "therapyName": "PMMB-187",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10364,
                    "pubMedId": 29066190,
                    "title": "Identification of new shikonin derivatives as STAT3 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29066190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5448,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LLL12 inhibited IL-6 mediated Stat3 signaling and growth of pancreatic cancer cell lines in culture (PMID: 21737619).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3592,
                "therapyName": "LLL12",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5061,
                    "pubMedId": 21737619,
                    "title": "LLL12 inhibits endogenous and exogenous interleukin-6-induced STAT3 phosphorylation in human pancreatic cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21737619"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8834,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 0617B inhibited survival of melanoma cells with activated Stat3 signaling in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27439479).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 4822,
                "therapyName": "Debio 0617B",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6765,
                    "pubMedId": 27439479,
                    "title": "Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27439479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5454,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FLLL32 inhibited Stat3 signaling and induced apoptosis in melanoma cell lines in culture (PMID: 20576164).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3862,
                "therapyName": "FLLL32",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5067,
                    "pubMedId": 20576164,
                    "title": "The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20576164"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5450,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LLL2 inhibited Stat3 signaling and cell proliferation in osteosarcoma cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 21340507).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3592,
                "therapyName": "LLL12",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5064,
                    "pubMedId": 21340507,
                    "title": "Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21340507"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8835,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 0617B inhibited survival of breast adenocarcinoma cells with activated Stat3 signaling in culture (PMID: 27439479).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 4822,
                "therapyName": "Debio 0617B",
                "synonyms": null
            },
            "indication": {
                "id": 3458,
                "name": "breast adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6765,
                    "pubMedId": 27439479,
                    "title": "Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27439479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8836,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 0617B inhibited survival of pancreatic carcinoma cells with activated Stat3 signaling in culture (PMID: 27439479).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 4822,
                "therapyName": "Debio 0617B",
                "synonyms": null
            },
            "indication": {
                "id": 4905,
                "name": "pancreatic carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6765,
                    "pubMedId": 27439479,
                    "title": "Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27439479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5446,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LLL12 inhibited Stat3 signaling and proliferaion, induced apoptosis in glioblastoma cell lines demonstrating constitutive Stat3 activation in culture (PMID: 21526200).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3592,
                "therapyName": "LLL12",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5059,
                    "pubMedId": 21526200,
                    "title": "The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21526200"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5400,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adrucil (fluorouracil) and OPB-31121 worked synergistically to inhibit growth of Stat3-positive gastric cancer cells sensitive or resistant to OPB-31121 in culture (PMID: 23402820).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3859,
                "therapyName": "Fluorouracil + OPB-31121",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5045,
                    "pubMedId": 23402820,
                    "title": "OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23402820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11373,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, C188-9 inhibited Stat3 signaling, inhibited growth of head and neck squamous cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 27027445).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 5961,
                "therapyName": "C188-9",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9260,
                    "pubMedId": 27027445,
                    "title": "Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27027445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8833,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 0617B inhibited survival of vulva squamous cell carcinoma cells with activated Stat3 signaling in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27439479).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 4822,
                "therapyName": "Debio 0617B",
                "synonyms": null
            },
            "indication": {
                "id": 2101,
                "name": "vulva squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6765,
                    "pubMedId": 27439479,
                    "title": "Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27439479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8831,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 0617B inhibited survival of non-small cell lung cancer cell lines with activated Stat3 signaling in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27439479).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 4822,
                "therapyName": "Debio 0617B",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6765,
                    "pubMedId": 27439479,
                    "title": "Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27439479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8832,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 0617B inhibited survival of head and neck squamous cell carcinoma cell lines with activated Stat3 signaling in culture (PMID: 27439479).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 4822,
                "therapyName": "Debio 0617B",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6765,
                    "pubMedId": 27439479,
                    "title": "Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27439479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5394,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, OPB-51602 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (PMID: 25609248).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3851,
                "therapyName": "OPB-51602",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5040,
                    "pubMedId": 25609248,
                    "title": "Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25609248"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5509,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WP1066 and Zolinza (vorinostat) combination treatment resulted in apoptosis in Stat3-positive chronic lymphocytic leukemia cells resistant to Zolinza (vorinostat) (PMID: 25636517).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3875,
                "therapyName": "Vorinostat + WP1066",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5079,
                    "pubMedId": 25636517,
                    "title": "The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25636517"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9186,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Bazedoxifene inhibited IL6-induced Gp130/Stat3 signaling in pancreatic cancer cell lines, resulted in growth inhibition in culture and in cell line xenograft models (PMID: 27535971).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 2737,
                "therapyName": "Bazedoxifene",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7003,
                    "pubMedId": 27535971,
                    "title": "Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535971"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5449,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LLL2 inhibited Stat3 signaling and cell proliferation in multiple myeloma cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 21520044).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3592,
                "therapyName": "LLL12",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5062,
                    "pubMedId": 21520044,
                    "title": "A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21520044"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9187,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Bazedoxifene and Gemzar (gemcitabine) synergistically inhibited IL6-induced Gp130/Stat3 signaling in pancreatic cancer cell lines, resulted in growth inhibition in culture (PMID: 27535971).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 4931,
                "therapyName": "Bazedoxifene + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7003,
                    "pubMedId": 27535971,
                    "title": "Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535971"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5507,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WP1066 inhibited Stat3 signaling and cell proliferation in human renal cell carcinoma cell lines in culture, and suppressed tumor growth in a cell line xenograft model (PMID: 20461084).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 2784,
                "therapyName": "WP1066",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5076,
                    "pubMedId": 20461084,
                    "title": "STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20461084"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5401,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Platinol (cisplatin) and OPB-31121 worked synergistically to inhibit growth of Stat3-positive gastric cancer cells in culture (PMID: 23402820).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3860,
                "therapyName": "Cisplatin + OPB-31121",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5045,
                    "pubMedId": 23402820,
                    "title": "OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23402820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9188,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Bazedoxifene and Taxol (paclitaxel) combination treatment resulted in enhanced inhibition of IL6-induced Gp130/Stat3 signaling and growth of pancreatic cancer cell lines in culture and in cell line xenograft models (PMID: 27535971).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 4930,
                "therapyName": "Bazedoxifene + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7003,
                    "pubMedId": 27535971,
                    "title": "Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27535971"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5455,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FLLL32 inhibited Stat3 signaling and cell proliferation in rhabdomyosarcoma cell lines demonstrating constitutive Stat3 activation in culture (PMID: 21109950).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3862,
                "therapyName": "FLLL32",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5065,
                    "pubMedId": 21109950,
                    "title": "Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21109950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5445,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LLL12 inhibited Stat3 signaling and proliferaion, induced apoptosis in medulloblastoma cell lines demonstrating constitutive Stat3 activation in culture (PMID: 21526200).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3592,
                "therapyName": "LLL12",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5059,
                    "pubMedId": 21526200,
                    "title": "The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21526200"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5452,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LLL12 inhibited Stat3 signaling and cell proliferation of rhabdomyosarcoma cell lines demonstrating constitutive Stat3 activation in culture (PMID: 21109950).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3592,
                "therapyName": "LLL12",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5065,
                    "pubMedId": 21109950,
                    "title": "Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21109950"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5396,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, OPB-51602 treatment resulted in partial response/stable disease in 24% (6/25) of non-small cell lung cancer patients, 83% (5/6) of patients responded harbored EGFR mutations and were positive for Stat3 (J Clin Oncol 32:5s, 2014 (suppl; abstr 8028)).",
            "molecularProfile": {
                "id": 20857,
                "profileName": "EGFR mut STAT3 pos"
            },
            "therapy": {
                "id": 3851,
                "therapyName": "OPB-51602",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5044,
                    "pubMedId": null,
                    "title": "Extended cohort study of OPB51602, a novel inhibitor of STAT3/5 activation, in non-small cell lung carcinoma.",
                    "url": "http://meetinglibrary.asco.org/content/127674-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5469,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY5 and Selumetinib (AZD6244) synergistically inhibited growth of Stat3-positive colorectal cancer cells harboring KRAS G12D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20929,
                "profileName": "KRAS G12D STAT3 pos"
            },
            "therapy": {
                "id": 3866,
                "therapyName": "LY5 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5470,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and Mekinist (trametinib) synergistically inhibited growth of Stat3-positive pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20929,
                "profileName": "KRAS G12D STAT3 pos"
            },
            "therapy": {
                "id": 3868,
                "therapyName": "Ruxolitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5465,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY5 and Mekinist (trametinib) synergistically inhibited growth of Stat3-positive pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20929,
                "profileName": "KRAS G12D STAT3 pos"
            },
            "therapy": {
                "id": 3863,
                "therapyName": "LY5 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5471,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and Selumetinib (AZD6244) synergistically inhibited growth of Stat3-positive pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20929,
                "profileName": "KRAS G12D STAT3 pos"
            },
            "therapy": {
                "id": 3869,
                "therapyName": "Ruxolitinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5468,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY5 and Mekinist (trametinib) synergistically inhibited growth of Stat3-positive colorectal cancer cells harboring KRAS G12D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20929,
                "profileName": "KRAS G12D STAT3 pos"
            },
            "therapy": {
                "id": 3863,
                "therapyName": "LY5 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5466,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY5 and Mekinist (trametinib) synergistically inhibited growth of Stat3-positive pancreatic cancer cells harboring KRAS G12V in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20930,
                "profileName": "KRAS G12V STAT3 pos"
            },
            "therapy": {
                "id": 3863,
                "therapyName": "LY5 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5467,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY5 and Mekinist (trametinib) synergistically inhibited growth of Stat3-positive colorectal cancer cells harboring KRAS G13D in culture (PMID: 25961376).",
            "molecularProfile": {
                "id": 20931,
                "profileName": "KRAS G13D STAT3 pos"
            },
            "therapy": {
                "id": 3863,
                "therapyName": "LY5 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5070,
                    "pubMedId": 25961376,
                    "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25961376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5506,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WP1066 inhibited Jak2 and Stat3 signaling, induced apoptosis in erythroleukemia cells carrying JAK2 V617F in culture (PMID: 18245540).",
            "molecularProfile": {
                "id": 20953,
                "profileName": "JAK2 V617F STAT3 pos"
            },
            "therapy": {
                "id": 2784,
                "therapyName": "WP1066",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2941,
                    "pubMedId": 18245540,
                    "title": "WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18245540"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7159,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INCB054329 and a Jak1 inhibitor synergistically inhibited Myc expression, Stat3 phosphorylation, and cell proliferation of multiple myeloma cell lines in culture, and suppressed tumor growth in xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 692).",
            "molecularProfile": {
                "id": 24500,
                "profileName": "MYC pos STAT3 pos"
            },
            "therapy": {
                "id": 2812,
                "therapyName": "INCB054329",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6114,
                    "pubMedId": null,
                    "title": "The BET inhibitor INCB054329 is synergistic with JAK1 inhibition in models of multiple myeloma",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/692.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8397,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of ISIS-STAT3rx (AZD9150) and Selumetinib (AZD6244) resulted in inhibition of Stat3 signaling and enhanced apoptosis in BRAF-mutant colorectal cancer cells (PMID: 25813020).",
            "molecularProfile": {
                "id": 26310,
                "profileName": "BRAF mut STAT3 pos"
            },
            "therapy": {
                "id": 4718,
                "therapyName": "AZD9150 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6639,
                    "pubMedId": 25813020,
                    "title": "HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25813020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20856,
            "profileName": "STAT3 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20857,
            "profileName": "EGFR mut STAT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20929,
            "profileName": "KRAS G12D STAT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20930,
            "profileName": "KRAS G12V STAT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20931,
            "profileName": "KRAS G13D STAT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20953,
            "profileName": "JAK2 V617F STAT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24500,
            "profileName": "MYC pos STAT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26310,
            "profileName": "BRAF mut STAT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}